Related Experiment Video
Updated: Jun 26, 2026
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Addressing the challenges for improving long-term outcomes in renal transplantation
1Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead NSW 2145, Australia. jeremy_chapman@wsahs.nsw.gov.au
Abstract:
Renal transplant patients lose their grafts most frequently from chronic allograft nephropathy and their lives from cardiac disease, malignancy, and infection. These are thus the challenges for renal transplant programs for this decade, just as acute rejection was the challenge of the last two decades. Most immunosuppressive protocols aim to minimize acute allograft rejection through heavy induction strategies and powerful but toxic maintenance therapies, counterbalanced by powerful and expensive infection prophylaxis. However, while the short-term results have improved steadily from the 1980s, and despite all the current efforts, the long-term success rates of renal transplants have not improved. Future aims include controlling both rejection and the long-term consequences of toxicity and infection risk. The biological facts that have determined our approach to the use of immunosuppressants have required us to try to balance the conflicting need for control of the allograft response and the inevitable toxicities of our drugs. The early period after transplantation requires maximum immunosuppressive efficacy with minimal ischemia reperfusion and good surgical-related wound healing. The latter period after transplantation requires less immunosuppressive efficacy and avoidance of chronic nephrotoxicity, cardiovascular, and malignancy risk factors. This usually leads to an induction strategy using a biological agent; a calcineurin inhibitor; an antiproliferative agent; and variable use of corticosteroids. In the long term, there are a variety of strategies for dose reduction or elimination of calcineurin inhibitors, incorporation of mammalian target of rapamycin inhibitors, and variable approaches to the risks of continued low-dose corticosteroids. The multiplicity of alternative strategies available testifies to the absence of evidence for a single dominant protocol and the urgent need to determine the relevant early indicators for measuring long-term success.
Insights
Renal transplant success remains limited by chronic nephropathy, cardiac disease, cancer, and infection. Current immunosuppression strategies balance graft survival with drug toxicity, highlighting the need for new approaches.
Area of Science:
- Nephrology
- Transplant Immunology
- Pharmacology
Background:
- Renal transplant recipients face graft loss from chronic allograft nephropathy and mortality from cardiac disease, malignancy, and infection.
- While acute rejection was the primary challenge previously, long-term success rates have stagnated despite improved short-term outcomes.
- Current immunosuppressive protocols aim to prevent acute rejection but carry significant toxicities and infection risks.
Purpose of the Study:
- To address the persistent challenges in renal transplantation, focusing on chronic allograft nephropathy, cardiac disease, malignancy, and infection.
- To re-evaluate immunosuppressive strategies balancing the need for graft protection with minimizing long-term drug toxicity.
- To identify early indicators for predicting long-term renal transplant success.
Main Methods:
- Review of current immunosuppressive protocols, including induction strategies and maintenance therapies.
- Analysis of the trade-offs between immunosuppressive efficacy and drug-related toxicities (nephrotoxicity, cardiovascular, malignancy).
- Exploration of long-term strategies such as calcineurin inhibitor dose reduction/elimination and mammalian target of rapamycin inhibitor incorporation.
Main Results:
- Despite advancements, long-term renal transplant success rates have not improved significantly.
- Standard immunosuppression involves biological agents, calcineurin inhibitors, antiproliferatives, and corticosteroids, with varying long-term management approaches.
- The lack of a dominant protocol underscores the need for better early indicators of long-term outcomes.
Conclusions:
- Future renal transplant programs must prioritize managing chronic allograft nephropathy, cardiac disease, malignancy, and infection.
- Optimizing immunosuppression requires balancing efficacy with the avoidance of long-term toxicities and infection risks.
- Further research is needed to establish reliable early indicators for predicting long-term renal transplant success and guide personalized treatment strategies.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:16Kidney Transplant III: Nursing Management
01:26Kidney Transplant II: Surgical Procedure
01:25Chronic Kidney Disease I: Introduction
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:28Chronic Kidney Disease III: Interprofessional Care